|Mr. Richard Pajer||Vice-Chairman of the Supervisory Board and Member of the Management Board||N/A||N/A||N/A|
|Mr. Armin Schulz||Member of the Management Board||N/A||N/A||N/A|
Elanix Biotechnologies AG develops and commercializes products for acute wound care, and dermatological and gynecological applications. The company develops and markets progenitor cell-based products that are used to regenerate tissue and promote healing in the treatment of burns, and gynecological and dermatological conditions. Its products include GYNrepair, a cream for genital external mucosa; and SKINrepair, a cream for skin that protects against external aggressions. The company is also developing FirstCover, an acute wound care tissue engineering product that is used to provide protection and healing for burns, and trauma and plastic surgery. In addition, it offers cell technology services. The company was formerly known as Porta Systems AG and changed its name to Elanix Biotechnologies AG in December 2015. Elanix Biotechnologies AG is based in Potsdam, Germany.
Elanix Biotechnologies AG’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.